ABSTRACT
This chapter discusses the importance of cancer endpoints and their relevance for economic evaluation. The two general categories of common cancer outcomes in clinical trials can be grouped into are: patient-centered endpoints and tumor-centered endpoints. The chapter discusses the relationship between overall survival and progression-free survival and response types. It explores the notion for quality-adjusted life-year and presented some examples of their use in health technology assessments. Comparing median survival times between treatments is a common way of showing clinical benefit in cancer trials and is useful when such effects are unambiguous. A fundamental component of clinical trials research is identification of a measurable outcome to delineate clinical benefit of new cancer treatments and further estimate the value they offer for patients and the healthcare system. Comparing median survival times between treatments is a common way of showing clinical benefit in cancer trials and is useful when such effects are unambiguous.
